Oral administration of <i>Clostridium butyricum</i> CGMCC0313‐1 reduces ovalbumin‐induced allergic airway inflammation in mice

Zhang, Juan; Shi, Zhaoling; Zeng, Ming‐Hua; Chun, Wei; Wu, Haixia; Liu, Mengyun; Jian-Qiong, Huang; Zheng, Yuejie; Sun, Xuegang

doi:10.1111/resp.12985

Cited by 50 publications

(45 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there has been no appreciable change in asthma mortality rates from 2006 through 2012, and asthma remains a global problem. In 2017, severe asthma was the focus of a wide variety of papers in Respirology ranging from reviews of the current state of severe asthma management and targeted therapies to experimental trials of probiotics for asthma control in murine models …”

Section: Asthmamentioning

confidence: 99%

“…In 2017, two studies examining the effect of microbiota on airway inflammation were reported in Respirology. Juan et al . demonstrated that oral administration of Clostridium butyricum CGMCC0313‐1 (a specific butyrate‐producing bacterial strain) reduced ovalbumin‐induced allergic airway inflammation in mice.…”

Section: Asthmamentioning

confidence: 99%

“…In 2017, severe asthma was the focus of a wide variety of papers in Respirology ranging from reviews of the current state of severe asthma management and targeted therapies [53][54][55] to experimental trials of probiotics for asthma control in murine models. 10,11 Co-morbidities Among patients with severe asthma, co-morbidities are common and may complicate management. As part of an invited review series in Respirology in 2017, Porsbjerg and Menzies-Gow 56 discussed the prevalence and impact of common co-morbidities in patients with severe asthma, and linked those co-morbidities to specific asthma phenotypes in order to assist clinicians with assessment.…”

Section: Key Pointsmentioning

confidence: 99%

“…Not only do severity and risk increase with age, but disease severity in childhood has been demonstrated to predict respiratory capacity later in life . Novel treatment strategies include a focus on the microbiome, with administration of probiotics for both prevention and treatment . Research regarding microbiota is of growing interest to multiple disciplines, and although meta‐analysis of human trials is inconclusive, use of probiotics remains a promising line of enquiry.…”

Section: Introductionmentioning

confidence: 99%

“…8,9 Novel treatment strategies include a focus on the microbiome, with administration of probiotics for both prevention and treatment. 10,11 Research regarding microbiota is of growing interest to multiple disciplines, and although meta-analysis of human trials is inconclusive, 12,13 use of probiotics remains a promising line of enquiry.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Year in review 2017: Chronic obstructive pulmonary disease and asthma

Benton

Lim

et al. 2018

Respirology

View full text Add to dashboard Cite

Section: Asthmamentioning

confidence: 99%

Section: Asthmamentioning

confidence: 99%

Section: Key Pointsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Year in review 2017: Chronic obstructive pulmonary disease and asthma

Benton

Lim

et al. 2018

Respirology

View full text Add to dashboard Cite

Contributions of the intestinal microbiome in lung immunity

2017

View full text Add to dashboard Cite

The intestine is a critical site of immune cell development that not only controls intestinal immunity but extra-intestinal immunity as well. Recent findings have highlighted important roles for gut microbiota in shaping lung inflammation. Here, we discuss interactions between the microbiota and immune system including T cells, protective effects of microbiota on lung infections, the role of diet in shaping the composition of gut micro-biota and susceptibility to asthma, epidemiologic evidence implicating antibiotic use and microbiota in asthma and clinical trials investigating probiotics as potential treatments for atopy and asthma. The systemic effects of gut microbiota are partially attributed to their generating metabolites including short chain fatty acids, which can suppress lung inflammation through the activation of G protein-coupled receptors. Thus, studying the interactions between microbiota and immune cells can lead to the identification of therapeutic targets for chronic lower respiratory diseases.

show abstract

Influence of gut and lung dysbiosis on lung cancer progression and their modulation as promising therapeutic targets: a comprehensive review

Thapa,

Magar,

Shrestha

et al. 2024

MedComm

View full text Add to dashboard Cite

Lung cancer (LC) continues to pose the highest mortality and exhibits a common prevalence among all types of cancer. The genetic interaction between human eukaryotes and microbial cells plays a vital role in orchestrating every physiological activity of the host. The dynamic crosstalk between gut and lung microbiomes and the gut–lung axis communication network has been widely accepted as promising factors influencing LC progression. The advent of the 16s rDNA sequencing technique has opened new horizons for elucidating the lung microbiome and its potential pathophysiological role in LC and other infectious lung diseases using a molecular approach. Numerous studies have reported the direct involvement of the host microbiome in lung tumorigenesis processes and their impact on current treatment strategies such as radiotherapy, chemotherapy, or immunotherapy. The genetic and metabolomic cross‐interaction, microbiome‐dependent host immune modulation, and the close association between microbiota composition and treatment outcomes strongly suggest that designing microbiome‐based treatment strategies and investigating new molecules targeting the common holobiome could offer potential alternatives to develop effective therapeutic principles for LC treatment. This review aims to highlight the interaction between the host and microbiome in LC progression and the possibility of manipulating altered microbiome ecology as therapeutic targets.

show abstract

Oral administration of Clostridium butyricum CGMCC0313‐1 reduces ovalbumin‐induced allergic airway inflammation in mice

Abstract: C. butyricum reduces OVA-induced allergic airway inflammation in mice and might be an additional or supplementary therapy for allergic asthma.

Cited by 50 publications

References 43 publications

Year in review 2017: Chronic obstructive pulmonary disease and asthma

Year in review 2017: Chronic obstructive pulmonary disease and asthma

Contributions of the intestinal microbiome in lung immunity

Influence of gut and lung dysbiosis on lung cancer progression and their modulation as promising therapeutic targets: a comprehensive review

Contact Info

Product

Resources

About